Title Image


Indication Oncology
Status ‒ ODD granted on December 23th, 2020.
‒ Registration Batch Manufacture planning.
Product Advantages Handa is utilizing its ONCORE™ technology to develop improved versions of Oncology drug for reducing the risk associated with sever side effect and improve bioavailability.
Potential Market According to the data in 2021 annual report of the brand company, the total sales of the brand drug were approximately US$2 billion.